Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

NEROFE monotherapy may be administered for a maximum of 12 cycles provided that the patient tolerates treatment and there is evidence of clinical benefit. If patients are receiving clinical benefit, they may continue past 12 cycles. Patients will be followed for a minimum of 30 days after the last dose of NEROFE monotherapy. After this 30 day period, patients will only be followed for the resolution of any ongoing adverse events.